Article
Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Medical oncology (Northwood, London, England) - 1 Jun 2016
Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Takeda Masahide, Okuda Yuji, Asano Mariko, Ito Hiroshi, Miura Masatomo
Abstract excerpt
We investigated the effects of polymorphisms in CYP2D6, ABCB1, and ABCG2 and the side effects induced by gefitinib on the pharmacokinetics of O-desmethyl gefitinib, the active metabolite of gefitinib. On day 14 after beginning therapy with gefitinib, plasma concentrations of gefitinib and O-desmethyl gefitinib were measured. Patients were grouped into three groups according to their combination of CYP2D6 alleles:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
